Study Title
Phase I Dose Escalation Study to Evaluate Tolerability and Safety of 225Ac-PSMA I&T in Patients With Metastatic Prostate Cancer
Study Details
Description:
225Ac-PSMA I&T is a radiopharmaceutical for therapy of prostate cancer. PSMA is overexpressed on prostate cancer cells. Actium-225 is an alpha emitting radionuclide. When PSMA I&T is labelled with Actium-225, it can be applied as therapy for prostate cancer.
Sponsor:
Erasmus Medical Center
Contacts:
Sui wai Lings.ling@erasmusmc.nl
+31107033612
Laurens Groenendijkimaging.trialbureau@erasmusmc.nl
+31107033612
Government Study Link:
NCT05902247 - Click here to see study onClinicalTrials.gov